Summary
In order to evaluate the influence of urinary flow rate at different pH values on the pharmacokinetics of the basic antiarrhythmic drug flecainide 7 healthy men received 50 mg flecainide under 4 different conditions:
-
1.
acidic urine (pH 5) and a high fluid load (125 ml · h−1)
-
2.
acidic urine (pH 5) and a low fluid load (25 ml · h−1)
-
3.
alkaline urine (pH 8) and a high fluid load (125 ml · h−1)
-
4.
alkaline urine (pH 8) and a low fluid load (25 ml · h−1)
At acidic pH the half-life, the amount of unchanged drug in the urine (Ae), renal clearance (CLR) and area under the curve (AUC) were independent of the fluid load.
At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml · min−1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng · ml−1 · h). When comparing acidic and alkaline urinary pH conditions, half-life, Ae, CLR, and AUC were different. For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml · min−1; AUC 976 vs 1480 ng · ml−1 · h. For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml · min−1; AUC 1045 vs 1540 ng · ml−1 · h.
It is concluded that urinary pH affects flecainide pharmacokinetics independently of urinary flow rate, and that a high flow enhances the elimination of flecainide only with an alkaline urine. This effect of flow rate does not appear to be of clinical relevance.
Similar content being viewed by others
References
Chang SF, Miller AM, Fox JM, Welscher TM (1984) Application of a bonded-phase extraction column for rapid sample preparation of flecainide from human plasma for HPLC analysis-detection by fluorescence or U.V. Ther Drug Monit 6: 105–111
Harrison DC, Winkle RA, Sami M, Mason JW (1981) Encainide: a new and potent antiarrhythmic agent. In: Harrison DC (ed) Cardiac arrhythmias, a decade of progress. GK Hall Medical Publishers, Boston
Holmes B, Heel RC (1985) Flecainide, a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 1–33
Holm ST (1979) A simple sequentially rejective multiple test procedure Scand J Stat 6: 65–70
Johnston A, Warrington S, Turner P (1985) Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. Br J Clin Pharmacol 20: 333–338
Muhiddin KA, Johnston A, Turner P (1984) The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. Br J Clin Pharmacol 17: 447–451
Sachs L (1978) Angewandte Statistik. Springer, Berlin Heidelberg New York
Salerno DM, Ganrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M (1986) Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther 40: 101–107
Vaughan Williams EM (1970) Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jansen E, Olesen KH (eds) Symposium on cardiac arrhythmias. AB Astra Sodertalje, Sweden, pp 449–472
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Ernst Mutschler on the occasion of his 60th birthday
Rights and permissions
About this article
Cite this article
Hertrampf, R., Gundert-Remy, U., Beckmann, J. et al. Elimination of flecainide as a function of urinary flow rate and pH. Eur J Clin Pharmacol 41, 61–63 (1991). https://doi.org/10.1007/BF00280108
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280108